Molecular Partners AG

Nasdaq MOLN · Schlieren-Zurich, Switzerland

Works in Hematology · Infectious disease · Oncology · Respiratory

Molecular Partners AG is a clinical trial sponsor based in Schlieren-Zurich, Switzerland, listed as Nasdaq MOLN. It has 1 active clinical trial with 138 planned participants, in Hematology, Infectious disease, Oncology and Respiratory. Since 2021 it has completed 5 trials and stopped 3 early.

Trial track record · since 2021

1Active trials138 planned participants
5Completed0 with results posted
3Stopped early38% of finished trials

Financials · Nasdaq MOLN

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 1 active trial

StageTrialStatus

Questions about Molecular Partners AG

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-21.

Approve Suite is not affiliated with Molecular Partners AG.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.